ArticlePLoS pathogens2026
Curtailment of Toll-like receptor signalling and cytokine production in dendritic cells by secreted products of Heligmosomoides polygyrus.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Dendritic cells (DCs) are the professional antigen-presenting cells responsible for recognition of pathogens and induction of appropriate adaptive immune responses. Many successful pathogens have evolved to release molecular products that can manipulate DC responses to dampen immunity. Here, we report that the excretory/secretory (ES) products of the intestinal helminth Heligmosomoides polygyrus bakeri profoundly repress the ability of murine and human DCs, differentiated under various conditions, to respond to canonical stimuli delivered through Toll-like Receptors (TLRs). H. polygyrus ES (HES) blocks production of pro-inflammatory cytokines, especially IL-6 and IL-12p70, at both the mRNA and secreted protein levels. In addition, upregulation of the costimulatory molecules CD40, CD80 and CD86 in response to LPS and other TLR ligands is inhibited. Although HES contains a mimic of host TGF-β, inhibition of DC activation is mediated independently of TGF-β signalling and by a HES protein fraction devoid of TGF-β-like proteins; we were not able to recapitulate inhibition with recombinant forms of 5 proteins identified in this fraction. HES pre-treatment of DCs blocks subsequent LPS-induced activation, excluding any direct interference with ligand binding. Inhibition can also be observed if HES is added up to 8 hours after LPS treatment, indicating modulation of later phase intracellular pathways. Analysis of activation of the NF-κB and MAPK signalling pathways and the time courses of CD40, IL-6, IL-12 and TNF expression confirms that HES does not affect the immediate-early phase of TLR-induced activation, but interferes with the ability of DCs to sustain activation and complete the inflammatory response programme, with IL-12 the most susceptible to inhibition as its production is initiated later than that of IL-6 and TNF. These data indicate finely staged changes in the maturation process of DCs upon HES treatment that have not previously been reported, helping explain how parasites like H. polygyrus are able to dramatically modulate host immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.